ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1061

Safety and Tolerability of Aminaphtone in Systemic Sclerosis Patients: A Four-year Follow-up

andrea cere, Emanuele Gotelli, Lercara Adriano, Carmen Pizzorni, sabrina Paolino, Alessandri Elisa, Maurizio Cutolo and Alberto Sulli, Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genova, Italy

Meeting: ACR Convergence 2022

Keywords: Raynaud's phenomenon, Systemic sclerosis, Therapy, alternative

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Systemic Sclerosis and Related Disorders – Clinical Poster I

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Recent studies proved that aminaphtone is an effective treatment for Raynaud’s phenomenon (RP) secondary to systemic sclerosis (SSc). Laser Speckle Contrast Analysis (LASCA) further demonstrated an increased peripheral blood perfusion in aminaphtone treated patients [1,2]. This drug is currently available only in a few countries.

The aim of this study was to evaluate long-term the profile of safety and tolerability of aminaphtone in SSc patients.

Methods: Seventy SSc patients taking aminaphtone were enrolled and followed for four years (mean disease duration 8±7 years, mean age 61±10 years). They met the 2013 EULAR/ACR criteria for SSc and started aminaphtone treatment due to active RP.

Patients were taking the following concomitant drugs: aspirin, immunomodulators, cyclic intravenous iloprost, endothelin receptor antagonists; none was taking either selexipag or phosphodiesterase type 5 inhibitors. Aminaphtone therapy was assessed and possible drug-related side effects were recorded. Patients were routinely evaluated with the Raynaud Condition Score (RCS) to assess disease severity, as well as by blood exams.

Results: The mean follow-up was 49±11 months. Aminaphtone was orally administered at 75 mg twice daily, as per our clinical practice. Six patients (8,6%) reported headache as side effect and had to reduce aminaphtone posology to 75 mg once daily, while maintaining clinical benefits. No other side effects related to the drug were observed during the follow-up. Seven patients (10%) increased the posology to 75 mg three times daily due to poor effectiveness, and further seven patients (10%) increased the posology to 75 mg three times daily only during the colder months of the year. Conversely, thirty-five patients (50%) reduced the treatment to 75 mg once daily during the warmest months of the year due to partial remission of symptomatic RP.

A subjective improvement of Raynaud’s symptoms, as assessed by the RCS, was already evident after 2 months of treatment in fifty-six patients (80%). Globally, patients referred a clinical improvement followed by a stabilization of Raynaud’s symptoms.

During the follow-up, blood tests did not reveal any significant alteration.

Conclusion: During an average follow-up of four years, aminaphtone showed a good tolerability and safety profile along with sustained efficacy in SSc patients with secondary RP, without any disabling or serious side effect. A randomized controlled trial is desirable to better evaluate the efficacy of the drug over time.

References: 1. Parisi S et al. Am J Int Med. 2015;3:204–209. 2. Ruaro B et al. Front Pharmacol. 2019;10:293.


Disclosures: a. cere, None; E. Gotelli, None; L. Adriano, None; C. Pizzorni, None; s. Paolino, None; A. Elisa, None; M. Cutolo, Bristol-Myers Squibb(BMS), Boehringer-Ingelheim, Amgen; A. Sulli, LABORATORY BALDACCI SPA.

To cite this abstract in AMA style:

cere a, Gotelli E, Adriano L, Pizzorni C, Paolino s, Elisa A, Cutolo M, Sulli A. Safety and Tolerability of Aminaphtone in Systemic Sclerosis Patients: A Four-year Follow-up [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/safety-and-tolerability-of-aminaphtone-in-systemic-sclerosis-patients-a-four-year-follow-up/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/safety-and-tolerability-of-aminaphtone-in-systemic-sclerosis-patients-a-four-year-follow-up/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology